There may be age-related differences in the plasma levels of cholestanol and lathosterol as well as in their respective ratios to cholesterol levels.
Symptom reduction was significantly correlated with poor metabolic adverse effects, including weight gain, elevated BMI, and higher total cholesterol.
Researchers performed a systematic review and meta-analysis to summarize and update the evidence regarding the effects of lifestyle intervention, including diet, on cardiometabolic risk among overweight and obese women with PCOS.
The lowering of lipoprotein(a) with alirocumab was found to independently contribute to the reduction in major adverse cardiovascular events in patients with recent acute coronary syndrome.
For patients with DVT, the presence of any component of metabolic syndrome is independently associated with an increased risk for VTE recurrence.
The blood levels of non-high density lipoprotein cholesterol were found to have a strong association with the long-term risk for a cardiovascular disease event.
Increased risk for heart failure also seen in group of participants without diastolic dysfunction
Lp(a) is a significant risk factor for macrovascular disease, albuminuria, and calcified aortic valve disease for patients with type 1 diabetes.
Suboptimal diet accounts for 18.2 percent of all cardiometabolic disease costs in the United States.
A greater quantity of oral nitrate-reducing bacteria was found to be associated with reduced plasma glucose and insulin resistance in young to middle-aged adults.